Minimizing Tuberculosis Risk in Patients Receiving Anti-TNF Therapy

Ann Am Thorac Soc. 2017 May;14(5):621-623. doi: 10.1513/AnnalsATS.201701-055ED.

Authors

Hanif Esmail^{1

2}, Robert J Wilkinson^{1

3

4}

Affiliations

¹ 1 Wellcome Center for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa.
² 2 Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
³ 3 Department of Medicine, Imperial College London, London, United Kingdom; and.
⁴ 4 The Francis Crick Institute, London, United Kingdom.

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antirheumatic Agents*
Humans
Latent Tuberculosis*
Tuberculosis*
Tumor Necrosis Factor-alpha

Substances

Antirheumatic Agents
Tumor Necrosis Factor-alpha

Grants and funding